Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.69 |
| ▸ | PPARD | Q03181 | 3/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.62 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GRK2 | P25098 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7443516 | 0.85 | NR1H3 (0.59) | PPARAPPARDCA12CA1CA2 | |
| SCHEMBL2731327 | 0.82 | NR1H3 (0.69) | PPARAPPARDCA12CA1CA2 | |
| SCHEMBL5654570 | 0.81 | PPARA (0.81) | PPARAPPARDCA12CA1CA2 | |
| SCHEMBL8889327 | 0.81 | KLKB1 (0.59) | PPARAPPARDCA2PTGER4NSD2 | |
| SCHEMBL4025504 | 0.80 | PTGER4 (0.67) | PPARAPPARDCA2NR1H3PTGER4 | |
| SCHEMBL9480783 | 0.80 | NR1H3 (0.66) | PPARAPPARDCA12CA1CA2 | |
| SCHEMBL4649471 | 0.79 | KMT2A (0.78) | PPARAPPARDCA12CA1CA2 | |
| SCHEMBL31119238 | 0.79 | GRM5 (0.58) | PPARAPPARDCA12CA1CA2 | |
| SCHEMBL13415490 | 0.79 | PTGER4 (0.70) | PPARAPPARDPTGER4NSD2POLB | |
| SCHEMBL11640029 | 0.79 | ALDH1A1 (0.57) | PPARAPPARDCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1091946-B1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTROEM HAKAN VILHELM (NL) | 2004-03-17 | — | — | EP | disclosed |
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-01-29 | — | — | US | disclosed |
| EP-1345909-A1 | PHENYLACETAMIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002048114-A1 | PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2002-06-20 | — | — | WO | disclosed |
| US-6291494-B1 | 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1091946-A1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTRÖM, Hakan Vilhelm (NL) | 2001-04-18 | — | — | EP | disclosed |
| EP-0690843-B1 | Formyl- or cyano- substituted indole derivatives having dopaminergic activity | UPJOHN CO (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000001680-A1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTROEM HAKAN VILHELM (NL) | 2000-01-13 | — | — | WO | disclosed |
| US-5639778-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0690843-A1 | INDOLETETRALINS HAVING DOPAMINERGIC ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021608-A1 | INDOLETETRALINS HAVING DOPAMINERGIC ACTIVITY | THE UPJOHN COMPANY (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | DCK, CCNK, CDK2 | PPARA 1179/4885PPARD 973/4885CA12 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.